4D-150 IVT (3E10 vg/eye)

Phase 3

MOLECULAR PARTNERS AG (MOLN)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

MOLNPhase 3$161M

EYLEA® (aflibercept) Injection 2 mg (0.05mL) Phase 3 Est. Readout

4D-150 IVT (3E10 vg/eye)• Macular Neovascularization Secondary to Age-Related Macular Degeneration480

Jun 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Macular Neovascularization Secondary to Age-Related Macular Degeneration

View Full Landscape

Drug Information

Target Indication

Macular Neovascularization Secondary to Age-Related Macular Degeneration

Clinical Trial

NCT06864988

Last updated: 8/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

MOLN

MOLECULAR PARTNERS AG

Biological Products, (No Diagnostic Substances)•Europe•NASDAQ

Related Pipeline

MP0420Phase 3

COVID-19

4D-150 IVT (3x10^10 vg)Phase 3

Diabetic Macular Edema (DME)

MP0250 plus BOR+DEXPhase 2

Multiple Myeloma in Relapse

[212Pb]Pb-MP0712Phase 2

Large Cell Neuroendocrine Carcinoma

MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1Phase 2

Leukemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts